Clinical trials in nuclear medicine: Present and future

TitreClinical trials in nuclear medicine: Present and future
Type de publicationArticle de revue
AuteurChaumet-Riffaud, P., Cachin, F., Couturier, Olivier-François , Desruet, M.-D., Kraeber-Bodéré, Françoise, Talbot, J.-N., Vuillez, J.-P.
EditeurElsevier Masson
TypeArticle scientifique dans une revue à comité de lecture
Titre de la revueMedecine Nucleaire
Mots-clés3' fluorothymidine f 18, article, benzamide derivative, breast cancer, Chemotherapy, Clinical research, clinical trial, Controlled trials, diagnostic procedure, fluorodeoxyglucose f 18, Human, lymphoma, medical research, Methodology, Nuclear Medicine, octreotide lu 177, Oncology, radiodiagnosis, radiopharmaceutical agent, Radiopharmaceuticals, unclassified drug, validation process, yttrium 90
Résumé en anglais

The particular status of radiopharmaceuticals, together with the positioning of nuclear medicine in multidisciplinary approach of oncology, lead to real difficulties for conception, validation and granting of clinical trials which are necessary for demonstrating clinical interest of new compounds, for diagnosis as well as for therapeutic use. This article is a presentation of some recent clinical trials conducted in nuclear medicine in France, showing its dynamism but also pointing out some encountered difficulties. These experiences could lead to reflexion in order to improve the clinical research performances, taking into account a scientific and regulatory context more and more constraining.

URL de la notice